Keywords
Sedation, Dental Anesthesia, Anxiolytics, IDD, Pharmacological
Abstract
Aims: To review the regulatory frameworks, professional guidelines and pharmacological considerations for administering anxiolytics to dental patients with intellectual and/or developmental disabilities (IDD).
Methods and Results: A comprehensive review was conducted of regulatory frameworks, guidelines from professional bodies and pharmacological considerations. The study found that specific permits are required for administering anxiolytics, continuous monitoring is essential and informed consent involves unique considerations for IDD patients. Key regulatory bodies include the New York State Education Department, New York State Department of Health and the Office for People with Developmental Disabilities, while professional guidelines are provided by the American Academy of Pediatric Dentistry, American Dental Association, American Society of Anesthesiologists and the New York State Dental Association.
Conclusion: Safe and effective use of anxiolytics in dental patients with IDD depends on strict adherence to regulatory and professional guidelines, as well as individualized care planning. Coordinated, patient-centered strategies that account for complex medical and behavioral needs are essential. Dental providers must be equipped to integrate behavioral techniques, environmental modifications and pharmacological support to improve access and outcomes for this underserved population.
Recommended Citation
Noorul Zaman, Kadher Mohaideen; Obermeyer, Izel Steinmann; Lyngdoh Prost, Jeremy L.; Tarangelo, Anne Marie; and Patrick, Tricia A.
(2026)
"Pharmacological and Regulatory Considerations for Anxiolytic Use in Dental Care for Patients with Intellectual and Developmental Disabilities,"
The New York State Dental Journal: Vol. 92:
No.
6, Article 2.
Available at:
https://commons.ada.org/nysdj/vol92/iss6/2